Iovance Biotherapeutics, Inc. Common Stock (IOVA) Stock Price

IOVAStock

$7.96+259.19%52W

Market Cap$3.60B

P/E—

PEG Ratio—

Div yield—

Beta0.88

IOVA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)99.97%

Price vs S&P 500 (4W)84.09%

VGM Score69.25

Book Value / Share (Quarterly)$1.62

P/TBV (Annual)2.58x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.65

Price vs S&P 500 (YTD)180.59%

Gross Margin (TTM)48.40%

Net Profit Margin (TTM)-89.09%

EPS (TTM)$-0.72

10-Day Avg Trading Volume17.41M

EPS Excl Extra (TTM)$-0.72

EPS (Annual)$-1.09

ROI (Annual)-55.89%

Gross Margin (Annual)34.28%

Cash / Share (Quarterly)$0.66

Revenue Growth QoQ (YoY)65.65%

ROA (Last FY)-42.82%

Revenue Growth TTM (YoY)34.55%

EBITD / Share (TTM)$-0.65

ROE (5Y Avg)-63.72%

Operating Margin (TTM)-92.72%

Cash Flow / Share (Annual)$-0.82

P/B Ratio4.05x

P/B Ratio (Quarterly)2.52x

Net Income / Employee (Annual)$-401,000

EV / Revenue (TTM)8.82x

Net Interest Coverage (TTM)-8.26x

ROA (TTM)-31.65%

EPS Incl Extra (Annual)$-1.09

Current Ratio (Annual)3.20x

Quick Ratio (Quarterly)3.74x

3-Month Avg Trading Volume16.16M

52-Week Price Return259.19%

Revenue / Employee (TTM)$333,300

Tangible BV / Share (Quarterly)$1.04

P/S Ratio (Annual)11.30x

Asset Turnover (Annual)0.29x

52-Week High$9.36

EPS Excl Extra (Annual)$-1.09

CapEx CAGR (5Y)-6.28%

Tangible BV CAGR (5Y)27.99%

26-Week Price Return111.90%

Quick Ratio (Annual)2.74x

13-Week Price Return86.28%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.34x

Enterprise Value$2.87B

Asset Turnover (TTM)0.36x

Book Value / Share Growth (5Y)-17.62%

Revenue / Employee (Annual)$270,300

Pretax Margin (Annual)-149.16%

Cash / Share (Annual)$0.72

3-Month Return Std Dev124.38%

Net Income / Employee (TTM)$-296,900

ROE (Last FY)-55.97%

Net Interest Coverage (Annual)-0.64x

EPS Basic Excl Extra (Annual)$-1.09

Receivables Turnover (TTM)4.01x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.72

ROI (TTM)-40.47%

P/S Ratio (TTM)9.16x

Revenue / Share (Annual)$0.74

Tangible BV / Share (Annual)$1.02

Price vs S&P 500 (52W)240.63%

Year-to-Date Return193.41%

5-Day Price Return-0.62%

EPS Normalized (Annual)$-1.09

ROA (5Y Avg)-48.85%

Net Profit Margin (Annual)-148.38%

Month-to-Date Return96.81%

Cash Flow / Share (TTM)$-1.96

EBITD / Share (Annual)$-1.03

Operating Margin (Annual)-153.08%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-63.61%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.72

P/TBV (Quarterly)3.93x

P/B Ratio (Annual)1.55x

Inventory Turnover (TTM)3.18x

Pretax Margin (TTM)-90.40%

Book Value / Share (Annual)$1.70

Price vs S&P 500 (13W)84.32%

Beta0.88x

Revenue / Share (TTM)$0.72

ROE (TTM)-40.51%

52-Week Low$1.76

vGradeC

gGradeB

mGradeA

vgmGradeB

IOVA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.13	-$0.11	+18.43%(+$0.02)
Q1 2026	May 7, 2026	-$0.15	-$0.19	-23.78%(-$0.04)
Q4 2025	Feb 24, 2026	-$0.18	-$0.18	-2.05%(-$0.00)
Q3 2025	Nov 6, 2025	-$0.26	-$0.25	+2.85%(+$0.01)
Q2 2025	Aug 7, 2025	-$0.28	-$0.33	-19.37%(-$0.05)

IOVA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.94

4.00

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$7.96
AMGNAmgen Inc	C	C	B	$430.76
GILDGilead Sciences Inc	C	B	B	$146.39
ARGXargenx SE American Depositary Shares	D	A	B	$1022.40
MRNAModerna, Inc. Common Stock	D	C	A	$142.94
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$203.63
BIIBBiogen Inc. Common Stock	C	D	B	$218.53
BNTXBioNTech SE American Depositary Share	C	C	C	$101.23
NBIXNeurocrine Biosciences Inc	C	B	C	$153.79
EXELExelixis Inc	C	B	B	$54.42
HALOHalozyme Therapeutics, Inc.	C	B	B	$106.09
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$354.93
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$135.03
RGENRepligen Corp	D	C	B	$178.11
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$117.41
PCVXVaxcyte, Inc. Common Stock	—	—	B	$60.24
QGENQIAGEN N.V.	C	C	B	$43.38
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$139.18
IBRXImmunityBio, Inc. Common Stock	F	A	B	$7.92
IMVTImmunovant, Inc. Common Stock	—	—	B	$40.03
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$56.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.47
CRSPCRISPR Therapeutics AG	D	B	C	$56.73
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.44
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$24.68
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$23.65
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$73.69
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.31
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.57
KODKodiak Sciences Inc Common Stock	—	—	B	$37.06
MESOMesoblast Limited American Depositary Shares	D	B	B	$16.77
ADMAADMA Biologics, Inc.	C	C	C	$9.43
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.18
VCELVericel Corporation	D	B	B	$39.46
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$35.99
ALVOAlvotech Ordinary Shares	C	D	C	$5.16
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.61
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.38
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$122.74
NVAXNovavax Inc	B	D	C	$9.62
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.73
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$25.99
REPLReplimune Group, Inc.	—	—	A	$15.30
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.40
VORVor Biopharma Inc. Common Stock	—	—	B	$22.59
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.59
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.71
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$13.59
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.81

About Iovance Biotherapeutics, Inc. Common Stock

Iovance Biotherapeutics is a biopharmaceutical company developing autologous TIL (tumor-infiltrating lymphocyte) cell therapies for solid tumors. The company's personalized approach harnesses patients' own immune cells to target and destroy cancer cells. Iovance is advancing toward U.S. regulatory approval and commercialization of what could be the first autologous T-cell therapy for solid tumor cancers.